Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18384364 | 0.99 | SMN1; SMN2 (0.44) | SMN1; SMN2CA2HDAC1HDAC3KMT2A | |
| SCHEMBL14727910 | 0.83 | MEN1 (0.36) | SMN1; SMN2HDAC1KMT2AMEN1EPHX2 | |
| SCHEMBL23280517 | 0.83 | SMN1; SMN2 (0.38) | SMN1; SMN2CA2HDAC1HDAC3KMT2A | |
| SCHEMBL31199169 | 0.79 | SMN1; SMN2 (0.40) | SMN1; SMN2CA2HDAC1HDAC3KMT2A | |
| SCHEMBL15646002 | 0.79 | SMN1; SMN2 (0.65) | SMN1; SMN2CA2KMT2AEPHX2NR1H4 | |
| SCHEMBL13248221 | 0.78 | ADORA3 (0.44) | SMN1; SMN2HDAC1HDAC3EPHX2NPC1 | |
| SCHEMBL13056381 | 0.77 | ADORA3 (0.43) | SMN1; SMN2HDAC1HDAC3EPHX2NPC1 | |
| SCHEMBL19658311 | 0.77 | SMN1; SMN2 (0.43) | SMN1; SMN2CA2HDAC1HDAC3KMT2A | |
| SCHEMBL26040572 | 0.76 | HPGD (0.31) | SMN1; SMN2HPGDHTT | |
| SCHEMBL14986208 | 0.76 | HPGD (0.38) | SMN1; SMN2KMT2AMEN1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3193933-B1 | ANTI-CD276 ANTIBODIES (B7H3) | US HEALTH (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20200199246-A1 | ANTI-CD276 ANTIBODIES (B7H3) | BIOMED VALLEY DISCOVERIES, INC. | 2020-06-25 | — | — | US | disclosed |
| US-10604582-B2 | Anti-CD276 antibodies (B7H3) | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH (US) | 2020-03-31 | — | — | US | disclosed |
| US-20180186890-A1 | ANTI-CD276 ANTIBODIES (B7H3) | THE US SECRETARY DEPARTMENT OF HEALTH (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180186890-A1 | ANTI-CD276 ANTIBODIES (B7H3) | THE US SECRETARY DEPARTMENT OF HEALTH (US) | 2018-07-05 | — | — | US | disclosed |
| US-9902724-B2 | Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
| US-20170037045-A1 | HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM | 3M INNOVATIVE PROPERTIES COMPANY | 2017-02-09 | — | — | US | disclosed |
| WO-2016044383-A1 | ANTI-CD276 ANTIBODIES (B7H3) | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604582-B2 | Anti-CD276 antibodies (B7H3) | CD274, HAVCR2, PDCD6 | SMN1; SMN2 1763/4885CA2 2591/4885HDAC1 1557/4885 |
| US-20180186890-A1 | ANTI-CD276 ANTIBODIES (B7H3) | CD274, HAVCR2, PDCD6 | SMN1; SMN2 1455/4885CA2 2894/4885HDAC1 1922/4885 |
| US-20200199246-A1 | ANTI-CD276 ANTIBODIES (B7H3) | CD274, HAVCR2, PDCD6 | SMN1; SMN2 1763/4885CA2 2591/4885HDAC1 1557/4885 |
| US-20170037045-A1 | HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM | IL2, ICOS, CD40 | SMN1; SMN2 4806/4885CA2 4352/4885HDAC1 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.